IGF1 and coronary artery disorder: As IGF-1, TPO and epinephrine levels are elevated in various disease states 22,34,35,48–50 and in patients who present with CHD 31–34,36,37, we wanted to evaluate their potential contribution to antiplatelet drug resistance.